期刊
NPJ VACCINES
卷 6, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41541-021-00414-4
关键词
-
资金
- US Department of Defense, Defense Health Agency
- US-UHS Department of Pediatrics RAMP grants [PED-86-10342]
- NIH [R01 AI154619]
- US Department of Defense [W81XWH-18-2-0040]
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-18-2-0040]
The study demonstrates that combining a nanoparticle vaccine with a potent adjuvant enhances SARS-CoV-2-specific durable adaptive immune T cell responses.
The emergence of variants of concern, some with reduced susceptibility to COVID-19 vaccines underscores consideration for the understanding of vaccine design that optimizes induction of effective cellular and humoral immune responses. We assessed a SARS-CoV-2 spike-ferritin nanoparticle (SpFN) immunogen paired with two distinct adjuvants, Alhydrogel(R) or Army Liposome Formulation containing QS-21 (ALFQ) for unique vaccine evoked immune signatures. Recruitment of highly activated multifaceted antigen-presenting cells to the lymph nodes of SpFN+ALFQ vaccinated mice was associated with an increased frequency of polyfunctional spike-specific memory CD4(+) T cells and K-b spike-(539-546)-specific long-lived memory CD8(+) T cells with effective cytolytic function and distribution to the lungs. The presence of this epitope in SARS-CoV, suggests that generation of cross-reactive T cells may be induced against other coronavirus strains. Our study reveals that a nanoparticle vaccine, combined with a potent adjuvant that effectively engages innate immune cells, enhances SARS-CoV-2-specific durable adaptive immune T cell responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据